Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21197731 | 1.00 | CA2 (0.43) | CA2MAPK14TSHRMAPK1USP2 | |
| SCHEMBL1966013 | 1.00 | CA2 (0.43) | CA2MAPK14TSHRMAPK1USP2 | |
| SCHEMBL4012285 | 0.90 | L3MBTL1 (0.47) | CA2MAPK14L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL1587457 | 0.90 | PLA2G4B (0.44) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL1587458 | 0.90 | PLA2G4B (0.44) | TSHRMAPK1USP2ALOX15HSD17B10 | |
| SCHEMBL1968021 | 0.88 | CA2 (0.43) | CA2MAPK14HSD17B10TMEM97SIGMAR1 | |
| SCHEMBL1586804 | 0.87 | RXRB (0.45) | PLA2G4BNR4A2NPC1POLBRAB9A | |
| SCHEMBL1586808 | 0.87 | RXRB (0.45) | PLA2G4BNR4A2NPC1POLBRAB9A | |
| SCHEMBL9149708 | 0.87 | MAPT (0.50) | CA2MAPK14MAPK1CYP3A4L3MBTL1 | |
| SCHEMBL16387647 | 0.87 | MAPT (0.46) | CA2MAPK14TSHRL3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936488-B | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3743419-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| CN-111936488-A | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019145360-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2109364-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
| US-5395910-A | Photostable polymers | AKZO NOBEL N.V. (NL) | 1995-03-07 | — | — | US | disclosed |
| EP-0550105-A2 | Liquid-crystalline polyurethanes, compositions of said liquid-crystalline polyurethanes, and a device for optical data storage comprising a liquid-crystalline polyurethane | Akzo Nobel N.V. (NL) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | CA2 4343/4885MAPK14 2118/4885TSHR 1235/4885 |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | PIGO, ENPP2, THPO | CA2 1477/4885MAPK14 1994/4885TSHR 4060/4885 |
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | CA2 4343/4885MAPK14 2118/4885TSHR 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.